Fresh analysis reveals that individuals who stop using popular weight-loss injections like Mounjaro or Wegovy may regain reduced body mass at a significantly accelerated pace than those who halt conventional diet and exercise regimens.
Research printed in a prominent health publication demonstrates that while overweight people often shed substantial amounts of their total mass while undergoing treatment, the mass comes back at an estimated rate of nearly a kilo each month after stopping.
"Individuals using these medications should be informed of the risk of rapid weight regain when the therapy is stopped," cautioned lead investigator Dr. Susan Jebb.
Such speed of regain suggests a reversion to original weight in about a year and a half.
Analyzing Approaches
The research, which looked at 37 of trials involving thousands of participants, contrasted the outcomes of GLP-1 agonists with other pills.
The team emphasize that individuals who lose weight through lifestyle changes alone generally have a slower creep back—perhaps 100 grams monthly—after stopping.
Explaining the Quick Regain
Doctors believe the mode of action of the injections is key to understanding the amplified weight return.
These medications imitate a natural hormone called glucagon-like peptide-1, which controls feelings of fullness.
"Long-term administration of the hormone levels far above than the body's typical production may cause the system to generate a reduced amount of its endogenous GLP-1, and could reduce responsiveness to its actions," said Dr. Adam Collins, a dietetics researcher.
"Discontinuation of this GLP-1 'fix' leads to appetite is uncontrolled, making binge eating far more likely."
A Lifelong Condition?
Medical guidelines advise the injections for individuals with obesity-related health risks, alongside recommended diet and exercise modifications.
Professionals say that, given the significant potential of weight regain, the treatment might need to be life-long.
This view is echoed by drug manufacturers, who state that the results "highlight the long-term nature of obesity," similar to managing conditions like diabetes.
Patient Accounts
Users who have come off the medication report a sudden resurgence of appetite.
"It was like something activating and I was suddenly starving," said an individual.
The struggle is compounded if patients have not established sustainable lifestyle or habit changes during therapy.
Growing Use
Figures suggest that millions of adults in the UK have tried these injections in the past year, with interest continuing to grow.
- Use is more common among women than men.
- The 40s and 50s demographic shows the highest level of interest.
- Many access the drugs through private healthcare rather than public health services.
Finally, clinicians stress that while the jabs are powerful tools for shedding pounds, they are not a standalone solution and long-term success hinges on ongoing lifestyle support.
